Treatment of knee osteoarthritis with a new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin: a multicenter, randomized, single-blind, non-inferiority clinical trial

Abstract

Objectives

To compare the efficacy and safety of a new formulation of a fixed dose combination of glucosamine sulfate (GS; 1500 mg) and bovine chondroitin sulfate (CS; 1200 mg) versus the reference product (RP) in patients with knee osteoarthritis (OA).

Methods

In this multicenter, randomized, single-blind trial, 627 patients with knee osteoarthritis (OA)—Kellgren-Lawrence grades 2 or 3 and mean score ≥ 40 mm in the WOMAC pain subscale—were randomized to receive GS/CS or the RP for 24 weeks. The primary efficacy endpoint was the absolute change in WOMAC pain subscale score. The secondary endpoints included the following: WOMAC total and subscale scores, overall assessment of the disease by the patient and the investigator, SF-12 score, OMERACT-OARSI response rate to the treatment, and rescue medication use.

Results

Mean reductions of WOMAC pain score were − 35.1 (sd = 23.2) mm in the GS/CS group and − 36.5 (sd = 24.9) mm in the RP group. The difference between the adjusted means of both treatments confirmed the non-inferiority of GS/CS versus the RP. Improvement was observed in pain, stiffness, physical function and total WOMAC score, as well as in overall OA assessment by the patient and the investigator for both groups. No improvement was observed in SF-12. The rate of OMERACT-OARSI responders was 89.4% in GS/CS group and 87.9% in the RP group. Headache and changes in glucose tolerance were the most frequent treatment-related adverse events.

Conclusions

The new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin sulfate was non-inferior to the RP in symptomatic treatment of knee OA, with a high responder rate and good tolerability profile.

Trial registration

ClinicalTrials.gov; Registration number NCT02830919; Date of registration: July 13, 2016; First randomization date: December 05, 2016).

Introduction

Osteoarthritis (OA) is an important cause of morbidity and functional impairment [1]. An increase of 31.4% in disability-adjusted life-years (DALYs) was observed for musculoskeletal diseases, including OA, from 2007 to 2017 [2]. The functional impairment caused by this disease has a significant socioeconomic impact: a review of studies published between 2006 and 2016 addressing the economic impact of OA showed that the average per patient direct costs of the disease in the United States ranged from US$ 1442 to US$ 21,335 per year [3].

Symptomatic knee OA is a highly prevalent disease, affecting nearly 14 million people in the United States [4]. A continuous growth in disease incidence is expected, due to increased life expectancy and the prevalence of obesity, which is a known risk factor for OA [4, 5].

Therefore, it is important to investigate therapies which can promote symptomatic relief without risks of severe adverse events. The current treatment algorithm of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) proposes the early introduction of symptomatic slow-acting drugs for OA (SYSADOAs), among which glucosamine sulfate and chondroitin sulfate are included [6].

Glucosamine is an aminosaccharide which corresponds to the main component of the glycosaminoglycans that form the matrix of connective tissue. Glucosamine acts by increasing the synthesis of proteoglycans, and by inhibiting enzymes that degrade the cartilage, such as collagenase, phospholipase A2 and lysosomal enzymes [7, 8]. Furthermore, glucosamine inhibits several pro-inflammatory mediators, such as nitric oxide, cyclooxygenase-2 and metalloproteinases [9].

Chondroitin sulfate consists of repeated chains of sulfate glycosaminoglycans, which are important components of the extracellular matrix of connective tissue. Its main functions include: granting resistance and elasticity to articular cartilage, inhibiting the synthesis of inflammatory mediators and catabolic enzymes, stimulating the synthesis of cartilage matrix components, and reducing chondrocyte apoptosis [10, 11]. Chondroitin sulfate may have different origins and may be obtained from different animal species. Currently, medicinal products which are extracted from avian, bovine, porcine, and marine (shark) sources are available worldwide. Randomized clinical trials with chondroitin sulfate from these different origins have already been conducted [10, 12].

In Brazil, a product containing glucosamine sulfate and chondroitin sulfate of shark origin, Ártico® (Eurofarma Laboratórios S.A., São Paulo, S.P., Brazil), is commercially available. However, due to increasing scarcity of many shark species, replacing sharks with another animal species as a source of raw material for chondroitin production has become necessary. This led to the search for other source of chondroitin sulfate for this product.

The purpose of this study was to evaluate the efficacy and safety of a new formulation for Ártico® using a fixed-dose combination of glucosamine sulfate (1500 mg) and chondroitin sulfate (1200 mg) of bovine origin provided in sachets for the treatment of knee OA and establishing its non-inferiority compared to the reference product (RP), Condroflex® (Zodiac Laboratórios S.A., São Paulo, S.P., Brazil). The choice of the comparator, which also contains chondroitin of bovine origin, was a requirement of the Brazilian food and drug regulatory agency (Agência Nacional de Vigilância Sanitária, ANVISA) for this clinical trial.

Patients and methods

Study design. This phase III, multicenter, randomized, single-blind, non-inferiority, parallel-group, active-controlled clinical trial was conducted from December 2016 to November 2018 at six Brazilian sites.

During the screening period, routine laboratory tests, knee x-rays, and physical exams were performed, and clinical histories and information on ongoing medications were collected. Radiographs were read at each study site, to determine the Kellgren-Lawrence grade of knee OA. All pharmacological treatments for OA were discontinued, and only paracetamol (500 mg up to 4 times daily) was allowed for residual pain. A specific washout period between screening and randomization visits was defined for each non-steroidal anti-inflammatory drug (NSAID) for patients undergoing such treatment.

The randomization visit (RV) was performed up to 15 days after the screening visit (SV). Clinical visits were scheduled 1 week (visit 1 – V1), 6 weeks (visit 2 – V2), 12 weeks (visit 3 – V3), 18 weeks (visit 4 – V4), and 24 weeks (final visit – FV) after the RV. Efficacy evaluations were performed at visits V2, V3, and FV. Both treatments were administered throughout the study, with a maximum treatment duration of 171 days.

Ethics, consent, and permissions

The study was conducted under international and local ethical standards and regulations, in accordance with the principles of the Declaration of Helsinki. It was approved by the Research Ethics Committee (RECs) of each participating institution before its beginning, with the following RECs and their respective sites: Faculdade de Medicina do ABC/ Fundação do ABC (Centro Paulista de Investigação Clínica and Instituto de Pesquisa Clínica e Medicina Avançada), Comitê Permanente de Ética em Pesquisa com Seres Humanos - COPEP (Clínica Clinilive), Comitê de Ética em Pesquisa em Seres Humanos do Hospital de Clínicas da Universidade Federal do Paraná (Centro de Estudos em Terapias Inovadoras), Comitê de Ética em Pesquisa da Associação de Assistência à Criança Deficiente (Associação de Assistência à Criança Deficiente), and Comitê de Ética em Pesquisa do Hospital Alberto Rassi – CEPHGG (Centro Internacional de Pesquisa).

Patients

Eligible patients met the following criteria:

• 1. ≥40 years old;

• 2. Diagnosed with knee OA as per the American College of Rheumatology (ACR) criteria;

• 3. Graded 2 or 3 by the Kellgren-Lawrence imaging classification;

• 4. Presented with pain in the target knee within 3 months prior to study screening;

• 5. Scored ≥40 mm in the visual analogue scale (VAS – 0 to 100 mm) for pain assessment (at the SV, and mean score ≥ 40 mm in the pain subscale of the Western Ontario and McMaster Universities (WOMAC) questionnaire at the randomization visit);

• 6. ACR functional status I to III.

All subjects gave written informed consent before inclusion in the study.

The main exclusion criteria included:

• 1. Diagnosis of other diseases of the knee;

• 2. Serious knee misalignment;

• 3. Serious trauma or surgery in the target knee within 6 months prior to enrollment,

• 4. Symptomatic OA of the ipsilateral hip;

• 5. Use of NSAIDs, dipyrone and opioid analgesics or narcotics from the SV, or washout period for these drugs shorter than defined by the protocol;

• 6. Use of oral, intravenous, or intramuscular corticosteroids within 30 days prior to the SV;

• 7. Intra-articular injection of corticosteroids and/or hyaluronic acid in the target knee within 6 months prior to the SV;

• 8. Use of diacerein, chloroquine, or soybean and avocado unsaponifiable extracts within the last 3 months; duloxetine hydrochloride over the last 30 days; glucosamine sulfate and/or chondroitin sulfate and strontium ranelate in the past 6 months;

• 9. Body mass index (BMI) ≥ 40 kg/m [2];

• 10. Fasting blood glucose > 110 mg/dL or glycated hemoglobin (HbA1c) > 6.5%.

In case of bilateral knee OA, a target knee was defined as the knee with the most severe pain symptoms according to medical evaluation.

Treatment and randomization

Eligible patients were randomized at a 1:1 ratio to one of the following study groups: [1] a group treated with the new formulation of a fixed-dose combination of glucosamine sulfate (1500 mg) and bovine chondroitin sulfate (1200 mg) (GS/CS group, Eurofarma Laboratórios S.A. São Paulo, S.P., Brazil) or [2] a group treated with the RP of glucosamine sulfate (1500 mg) and bovine chondroitin sulfate (1200 mg) (Condroflex®, Zodiac Laboratórios S.A., São Paulo, S.P., Brazil). In both groups, the drug was supplied in sachets, and a daily dosage of one sachet was administered. Randomization was made through an interactive web response system (IWRV) integrated to the electronic case report form (eCRF), by which a code was informed to identify the product to be dispensed to each subject. Since the organoleptic properties (powder, color, and flavor) are different in both study treatments, the study was single-blinded, and only the patient and the study pharmacist were unblinded to the assigned treatment. The investigator and all other members of the study team were kept blind to the study treatment. Patients were instructed not to reveal the characteristic of the product in use to the investigator throughout the study. The sachet package (primary package) given to both groups had a similar characteristic, and identical labels were stuck to the sachets of both products to hide all available information and differences in the original packaging. The single-blind nature of the study was kept by using boxes (secondary package) with similar appearance and form for both study treatments.

Efficacy and safety evaluations

The following efficacy evaluations were performed:

• Primary endpoint:

  • Absolute change in pain subscale score on WOMAC questionnaire (normalized for 0 to 100 mm) at week 24 versus baseline score.

• Secondary endpoints:

  • Absolute change in pain, stiffness, and function subscale scores on WOMAC questionnaire (normalized for 0 to 100 mm) throughout the treatment in relation to baseline score;

  • Absolute change in overall assessment of the disease by the patient and investigator throughout the treatment, using the visual analogue scale (VAS) (0 to 100 mm), in relation to baseline assessment;

  • Absolute change in score of physical and mental components of Short Form-12 (SF-12) questionnaire at week 24 versus baseline score;

  • Treatment response rate throughout the study, according to the Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria;

  • Number of tablets of rescue medication administered during treatment.

The WOMAC questionnaire was administered by a professional duly trained for such a purpose in each study site, and patients were instructed to give answers only considering symptoms in the target knee within the previous 48 h.

Rescue medication consisted of paracetamol (500 mg). Up to 4 tablets/day was allowed for no more than 5 consecutive days. Patients were instructed not to use paracetamol within 12 h before visits in which efficacy analyses were scheduled.

Safety evaluation outcomes included:

• Incidence and profile of adverse events (AEs);

• Frequency of discontinuations due to AEs and laboratory abnormalities.

Statistical analysis

Sample size calculations were based on the evaluation of a non-inferiority hypothesis of GS/CS compared to the reference product, established in terms of the primary efficacy variable. It was considered the one-sided means test for two independent samples (significance level = 2.5), the difference between the treatment means equal to zero, a standard deviation of 98 mm, and a non-inferiority margin of 35 mm for the pain subscale of the WOMAC score (ranging from 0 to 500 mm, or equivalent to 7 mm in a normalized scale from 0 to 100 mm). We determined that 250 patients (125 in each study group) would give 80% of power to demonstrate the non-inferiority of the investigational product compared to the reference product. The estimated rate of patient withdrawal from the per protocol population (PP) was 20%, with randomization of 314 subjects planned.

In order to update the standard deviation sample size estimations, a blinded interim analysis was conducted after 214 patients completed the study. The estimated standard deviation value was 134.6 mm and the adjusted sample size was 468 patients. Considering a withdrawal rate from the PP population of 20%, it was established that 586 patients would be enrolled in the study.

The efficacy evaluations were performed in the intention to treat (ITT) population and in the PP population. The ITT population was defined as all randomized study subjects that received at least one dose of the study drug and that had at least one primary assessment of efficacy. The PP population was composed of all subjects of the ITT population that completed the study, that had a drug adherence between 80 and 120% and that were compliant with all study requirements. The safety evaluations were conducted to all randomized study subjects that received at least one dose of the study drug.

A covariance analysis model was adjusted for assessment of the primary efficacy variable, with the treatment group as a fixed factor and the site and baseline WOMAC pain subscale score as covariates. The evaluation of non-inferiority of GS/CS versus the reference product was conducted based on the two-sided confidence interval (95%) for the difference between the means of absolute changes of the WOMAC pain subscale score between study groups, with the non-inferiority of GS/CS combination versus the reference product being stated if the upper limit of the confidence interval was lower than the non-inferiority margin of 7 mm.

For all secondary efficacy variables, a two-sided confidence interval (95%) was established for the difference between the groups. Covariance models and analysis of variance models for repeated measures were adjusted for group comparisons.

Patient distribution according to OMERACT-OARSI treatment response criteria was evaluated through a generalized linear model for repeated measures, considering the binomial response, treatment, and week as factors, and treatment*week interaction, and site as covariates.

The mixed-effects Poisson regression model was used in the analysis of the number of tablets of rescue medication administered per week, pre- and post-treatment.

Safety analyses were performed through descriptive statistics and confidence intervals (95%).

Results

Demographics and baseline clinical characteristics

A total of 858 patients were screened for the study, 627 of which fulfilled the eligibility criteria and were randomized. A total of 314 patients were assigned to the GS/CS group and 313 patients were assigned to the RP group. All patients received the treatment to which they were randomized, except for a patient who was randomized to the GS/CS group but received the reference drug at V3. This patient was discontinued at V4. Among randomized patients, 489 (78%) completed the study (251 (79.9%) in the GS/CS group and 238 (76%) in the reference group). The most frequent reasons for early treatment discontinuation were use of forbidden medications, inadequate use of rescue therapy, and withdrawal of consent. Figure 1 shows patients’ disposition in both study groups and populations.

Fig 1

Disposition of study patients

Demographics and baseline clinical characteristics of the studied population are presented in Table 1. Most patients were female and Caucasian, with a median BMI of 30.6 kg/m², indicating obesity grade I. Patients’ age ranged from 40 to 86 years, predominantly over 60 (65.9%). Mean OA duration was around 7 years in both groups. Most patients were Kellgren-Lawrence grade 2 on the target knee (67% in both groups). The mean value (standard deviation, sd) of the WOMAC questionnaire pain subscale score was approximately 67.2 (sd = 13.4) mm for the studied population. Systemic arterial hypertension was the most frequent comorbidity in both groups. Demographics and clinical characteristics of the PP population were similar to the ITT population, and treatment groups were homogeneous for these characteristics.

Table 1 Baseline clinical and demographic characteristics in PP population

The mean value of treatment adherence in the PP population was 97.1 (sd = 4) % in the GS/CS group and 96.1 (sd = 4.8) % in the reference group, with no statistically significant difference between the groups.

Efficacy Outcomes

Primary efficacy analysis

The mean value of the pain subscale score at baseline was 66.3 (sd = ±13.2) mm in GS/CS group and 68.1 (sd = 13.5) mm in the reference group. Mean reductions of the WOMAC pain subscale score on week 24 compared to baseline in the PP population was − 35.1 (sd = 23.2) mm (a 53% reduction) in the GS/CS group and − 36.5 (sd = 24.9) mm (a 53.7% reduction) in the reference group, with a between-treatments difference of 1.4 mm (CI = 95%: − 3.2 mm; 6 mm). Adjusted estimates obtained from a covariance analysis model showed a reduction in pain score at the end of the study of − 30.9 (±2) mm in GS/CS group and − 31.8 (±2) mm in the reference group, with a between-treatments difference of adjusted means of 0.9 (±2.1) mm and respective CI (95%) equal to (− 3.21 mm; 4.99 mm). In the ITT population, adjusted estimates showed a mean reduction of the WOMAC pain subscale of − 29.5 (sd = 1.7) mm in the GS/CS group and − 28.9 (sd = 1,7) mm in the RP group on week 24 compared to baseline, with a between-treatments difference of − 0.5 (CI 95%: − 4.2 mm; 3.1 mm). In both PP and ITT population, the upper limit of the confidence interval of the difference between the adjusted mean of both treatments for the pain subscale was lower than the non-inferiority margin of 7 mm established prior to the study, confirming the non-inferiority of the new GS/CS fixed-dose combination versus the RP.

Secondary efficacy analyses

Table 2 shows the changes in the WOMAC score and Table 3 shows the results for the other secondary efficacy endpoints. No statistically significant difference between the groups was observed for secondary efficacy evaluations conducted in all timepoints throughout the study, both in PP and in ITT populations. These data support the non-inferiority of the new GS/CS formulation versus the reference product.

Table 2 Changes in the WOMAC score during the treatment in PP population^a

Table 3 Secondary efficacy analyses during the treatment in PP population^a

Improvements were observed in both treatment groups in pain, stiffness, physical function and total WOMAC score 6, 12, and 24 weeks after treatment initiation. A statistically significant improvement was also observed in the VAS for overall OA assessment, both by the patient and the investigator. These outcomes are represented in Fig. 2.

Fig. 2

WOMAC a “pain” subscale, b “stiffness” subscale, c “physical function” subscale and d total score; e VAS overall assessment of OA by the patient; f VAS overall assessment of OA by the physician. Adjusted estimates and two-sided CI (95%) of absolute ranges for each variable in PP population. P value indicates the differences between the treatment groups and between week 24 visit and baseline assessment. OA: osteoarthritis; RP: reference product; VAS: visual analogue scale; WOMAC: Western Ontario and McMaster Osteoarthritis questionnaire

No statistically significant effects of treatment related to physical (p = 0.369) and mental (p = 0.089) components of the SF-12 questionnaire were observed 24 weeks after treatment initiation, with no difference between groups.

A progressive increase in the response rate to treatment according to OMERACT-OARSI criteria was observed throughout the study (Table 3). The overall response rate was 89.4% in the GS/CS group and 87.9% in the reference group, with a between-groups difference of 1.5 (CI 95%: − 4.5%; 7.5%).

The median number of tablets of rescue medication used for pain in the knees during the total treatment period was 12 tablets in the GS/CS group and 13 tablets in the reference group. Table 2 shows the number of tablets of rescue treatment used at each study visit.

Safety

A total of 1076 AEs were reported during the study, of which 504 occurred in the GS/CS group and 572 in the reference group (most of mild intensity). The number of AEs considered related to the study treatment were 116 (23%) in the GS/CS group and 160 (28%) in the reference group.

The most frequent treatment-related AE was headache, reported by 12.7% of the patients in the GS/CS group and 14.4% of the patients in the reference group, followed by impaired glucose tolerance, reported by 2.9% of patients in the GS/CS group and 5.5% of patients in the reference group. A summary of the AEs with incidence ≥5% in the safety population is described in Table 4.

Table 4 Adverse events observed in the safety population

Five serious adverse events (SAEs) were reported by 3 patients from the GS/CS group (intestinal obstruction and abdominal hernia repair; nephrolithiasis and urinary tract infection; and amyotrophic lateral sclerosis), and 2 SAEs were reported by 2 patients in the reference group (road traffic accident and cholecystitis); none of the reported SAEs were assessed as related to the study treatment. No deaths occurred during the study.

Discussion

Both formulations of a fixed-dose combination of glucosamine sulfate and bovine chondroitin sulfate provided in sachets provided clinically relevant improvement of pain and physical function in patients with primary OA of the knee, establishing proof of non-inferiority between the two products. An improvement in overall OA assessment was reported both by patients and investigators, and a progressive increase was observed in the rate of treatment responders according to OMERACT-OARSI criteria throughout the study, with over 80% of responders in each study group at the end of the 6-month treatment. On the other hand, no significant improvement in quality of life was observed in either group, as assessed by the SF-12 questionnaire.

The large number (> 600) of randomized patients is one of the strengths of this study. The study was conducted in several research sites, with evaluations performed during 24 weeks of treatment. Different endpoints were used, including a WOMAC questionnaire, VAS for overall disease assessment by the patient and the investigator, an SF-12 questionnaire, and treatment response rate evaluation as per OMERACT-OARSI criteria. The choice of comparator was a requirement of the Brazilian food and drug regulatory agency (Agência Nacional de Vigilância Sanitária, ANVISA), since the chondroitin sulfate substrate of the reference product is of bovine origin. The blinding strategy of the study treatments enabled keeping the single-blind nature of the study, despite drugs having different organoleptic characteristics.

The need for replacing the raw material for chondroitin manufacturing has led to the development of a new formulation and, therefore, is the initiative for this clinical trial. A fixed-dose combination of glucosamine sulfate and chondroitin sulfate obtained from shark cartilage (Ártico®, Eurofarma Laboratórios S.A., São Paulo, S.P., Brazil), is currently marketed in Brazil as a prescription product approved for medical use by ANVISA, based on the demonstration of its efficacy and safety in previous clinical trials [13, 14]. However, due to the need to protect increasingly endangered shark species whose populations have exponentially decreased over the last five decades, with no signs of a satisfactory recovery [15, 16], a new source of raw material for chondroitin has become necessary. The option of using bovine cartilage as a substrate for the new formulation was based on the wide availability of this raw material in the Brazilian territory, as well as on evidence of bovine chondroitin efficacy available in the medical literature.

Our findings support the efficacy and safety of the glucosamine sulfate and chondroitin sulfate combination. However, there is still much discussion in the scientific literature about the role of this combination in knee OA, due to controversial results from previous clinical trials. In a randomized, double-blind trial conducted in Spain, the glucosamine sulfate and chondroitin sulfate combination was not observed to be superior to a placebo during a 6-month treatment trial [17].

On the other hand, our results are similar to those from the MOVES study, in which the efficacy of the glucosamine hydrochloride and chondroitin sulfate combination was compared to celecoxib. Despite the differences in the methodologies between the studies, the high OMERACT-OARSI response rate (79% both for the glucosamine/chondroitin sulfate combination and for celecoxib) observed in the MOVES study was similar to the response rate found in our study [18]. The improvement in pain and physical function by the WOMAC questionnaire during 6 months of follow-up was also observed in both studies.

The safety profile of the new formulation was similar to the comparator drug. Headaches and changes in glucose tolerance were the most frequent treatment-related AEs. Different results regarding the effect of glucosamine on glucose metabolism are found in the literature [19]. No SAEs related to the study treatment were reported during the study. This data is supported by a systematic review and meta-analysis about safety of symptomatic slow-acting drugs for OA, which did not show any increase in the risk of SAEs or severe AEs compared to placebo [20].

One factor that could impact our study results was the use of paracetamol as a rescue therapy for OA residual pain. However, the use of the rescue therapy was low in both groups, and it would not be ethical to forbid the use of a pain relief medication during the study. Aiming to reduce the influence of the pain relief medication in questionnaire responses, its use was forbidden within 12 h prior to efficacy evaluations performed in the study. The Kellgren-Lawrence grade of knee OA was evaluated by a physician at each study site. The lack of a central reading system of the radiographs could introduce greater variability in the imaging interpretation and was another limitation. Another point to be mentioned is the proportion of over 60% of Caucasian people in this Brazilian study. According to the Brazilian Institute of Geography and Statistics (IBGE, Instituto Brasileiro de Geografia e Estatística), the self-reported race is white for about 40% of the Brazilian population [21], but we have seen more than 60% of white people in our sample. This could be explained by a larger number of patients who came from centers in São Paulo and Paraná, where there is a higher proportion of whites compared to other regions of the country. Finally, the high drop-out rate of over 20% is also a limitation of the present study, but a per protocol analysis did not show group differences.

Conclusion

In conclusion, this clinical study showed that the new formulation of a fixed-dose combination of glucosamine sulfate and chondroitin sulfate of bovine origin is not inferior to the reference product. The new combination showed a good safety profile in this large population studied. New controlled clinical studies with a large number of patients and evaluating treatment response rate with the combination of glucosamine sulfate and chondroitin sulfate are warranted.